Search Results
Your search for 3 matches 15623 pages
Showing 14501 - 14550Ofatumumab Maintenance Improves Progression-Free Survival in Responders to Second- or Third-Line CLL Treatment
In an interim analysis of the phase III PROLONG trial reported in The Lancet Oncology, van Oers et al found that maintenance therapy with ofatumumab (Arzerra) prolonged progression-free survival vs observation in patients with chronic lymphocytic leukemia in complete or partial remission after...
Improved Progression-Free Survival With Trabectedin vs Dacarbazine After Conventional Chemotherapy in Advanced Liposarcoma or Leiomyosarcoma
In a phase III trial reported in the Journal of Clinical Oncology, Demetri et al found that treatment with trabectedin significantly improved progression-free survival vs dacarbazine in patients with advanced liposarcoma or leiomyosarcoma after prior conventional chemotherapy. Interim analysis of...
Breast Cancer Symposium: Recurrence Rates for Ductal Carcinoma in Situ Treated Between 1978–2010
A new retrospective analysis explored local recurrence rates for women with ductal carcinoma in situ (DCIS) treated between 1978 and 2010. In the research (Abstract 32) by Van Zee et al, to be presented September 25 at the 2015 Breast Cancer Symposium, in San Francisco, investigators evaluated a...
Antifungal Agent Increases Risk of Cutaneous Squamous Cell Carcinoma in Some Lung Transplant Recipients
Voriconazole, commonly used to prevent and treat fungal infections in lung transplant recipients, significantly increases the risk for cutaneous squamous cell carcinoma in this population, according to a new study by University of California San Francisco researchers. The team recommends physicians ...
Phase III Trial Shows No Benefit of Adjuvant GM-CSF or Peptide Vaccine in High-Risk, Resected Melanoma
In a phase III trial (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group E4697 trial) reported in the Journal of Clinical Oncology, Lawson et al found no relapse-free or overall survival benefit with adjuvant yeast-derived granulocyte-macrophage...
Study Finds CD38-Targeted Antibody Daratumumab Active in Relapsed Multiple Myeloma
In a phase I/II trial reported in The New England Journal of Medicine, Lokhorst et al found that the CD38-targeting human IgG1κ monoclonal antibody daratumumab had an acceptable safety profile and produced durable responses in relapsed multiple myeloma. Study Details In the dose-escalation...
Long-Term Remissions Reported in CLL Personalized Cell Therapy Trial
In the first trial of the University of Pennsylvania's personalized cellular therapy for chronic lymphocytic leukemia (CLL), 8 of 14 patients responded to the therapy, with some complete remissions continuing past 4.5 years. These results, published by Porter et al in Science Translational...
Pembrolizumab Treatment May Cause Immune Cells to Express Markers of Reinvigoration
Treating patients with metastatic melanoma with the immunotherapy drug pembrolizumab (Keytruda) caused immune cells called CD8-positive T cells in the patient’s blood to express markers of reinvigoration, according to data being presented at the CRI-CIMT-EATI-AACR International Cancer...
Chemotherapy Pretreatment May Boost Effectiveness of CAR T-Cell Therapy in Patients With Lymphoma and Leukemia
A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...
Long-Term Infusion of Immunotherapy May Reduce Pain in Children With High-Risk Neuroblastoma
Changing the infusion delivery method of the monoclonal antibody ch14.18/CHO (dinutuximab-beta, the European counterpart of dinutuximab [Unituxin]) in combination with interleukin-2 and oral 13-cis-retinoic acid from short-term infusion to long-term infusion in the treatment of children with...
AACR’s Cancer Progress Report Details Major Advances in Cancer and Rising Costs of Treatment
The American Association for Cancer Research (AACR) 2015 Cancer Progress Report highlighted the accelerated pace of the number of U.S. Food and Drug Administration (FDA)-approved targeted therapies over the past 5 years, which reached 52 this year; the dramatic increase in the 5-year survival rate...
Study Finds No Recurrence-Free Survival Benefit of Adjuvant Sorafenib in Hepatocellular Carcinoma After Resection or Ablation
In the phase III STORM trial reported in The Lancet Oncology, Bruix et al found no benefit with adjuvant sorafenib (Nexavar) treatment in patients who had undergone resection or ablation for hepatocellular carcinoma. Study Details In this double-blind trial, 1,114 patients from 202 sites in 28...
Japanese Phase II Trial Shows Activity of Nivolumab in Platinum-Resistant Ovarian Cancer
In a Japanese phase II trial reported in the Journal of Clinical Oncology, Hamanishi et al found that the anti–PD-1 (programmed cell death protein 1) antibody nivolumab (Opdivo) was active in patients with relapsed or advanced platinum-resistant ovarian cancer. Study Details In the study,...
Statistical Model May Identify Patients Most Likely to Benefit From Mesothelioma Surgery
A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma, according to a report published by Leuzzi et al in The Annals of Thoracic Surgery. Malignant pleural mesothelioma is an aggressive...
Trebananib Plus Sunitinib Active in Metastatic Clear Cell Renal Cell Cancer
In a phase II study reported in the Journal of Clinical Oncology, Atkins et al found that combined treatment with the recombinant peptide-Fc fusion protein trebananib and the vascular endothelial growth factor (VEGF) inhibitor sunitinib (Sutent) was active in metastatic renal cell cancer and...
BRAF Inhibition Successful in Relapsed/Refractory BRAF V600E–Mutant Hairy Cell Leukemia
In two phase II studies reported in The New England Journal of Medicine, Tiacci et al found that the BRAF inhibitor vemurafenib (Zelboraf) produced responses in nearly all patients with BRAF V600E–positive hairy cell leukemia who relapsed after treatment with a purine analog or who had...
ASCO Clinical Practice Guideline Update: Systemic Therapy for Stage IV NSCLC
As reported in the Journal of Clinical Oncology by Masters et al, ASCO has issued a clinical practice guideline update on systemic therapy for stage IV non–small cell lung cancer (NSCLC). Recommendations are based on an update committee systematic review of randomized controlled trials...
WCLC: Adding Bevacizumab to Chemotherapy Does Not Improve Overall Survival in Early-Stage NSCLC
Adding the monoclonal antibody bevacizumab (Avastin) to chemotherapy for patients with surgically removed non–small cell lung cancer (NSCLC) did not improve overall survival, according to research (Abstract PLEN04.03) presented at the 16th World Conference on Lung Cancer (WCLC) in Denver,...
WCLC: Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study (Abstract ORAL11.01) by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed...
Phase II Trial Shows Greater Activity With Lenalidomide/Rituximab vs Lenalidomide in Recurrent Follicular Lymphoma
In a phase II trial (Cancer and Leukemia Group B 50401/Alliance) reported in the Journal of Clinical Oncology, Leonard et al found that the addition of rituximab (Rituxan) to lenalidomide (Revlimid) produced a higher response rate and longer time to progression than lenalidomide alone in patients...
Call for APOS 2016 Award Nominations
The American Psychosocial Oncology Society (APOS) will be celebrating 30 years of psychosocial oncology at the 13th Annual APOS Conference, to be held March 3 to 5, 2016, in San Diego. Colleagues, mentors, students, and others who have made an impact on psychosocial oncology can be nominated for an ...
ASCO Releases Updated Policy Statement on Genetic and Genomic Testing for Cancer Susceptibility
The American Society of Clinical Oncology (ASCO) issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical Oncology, the statement reviews the ways in which new technologies are transforming the assessment and identification of ...
Activity of Colony-Stimulating Factor-1 Receptor Kinase Inhibitor in Tenosynovial Giant Cell Tumors
In a phase I study reported in The New England Journal of Medicine, Tap et al found that a newly developed inhibitor of colony-stimulating factor-1 receptor (CSF1R) kinase showed activity in tenosynovial giant cell tumors. CSF1 gene expression is elevated in most such tumors. The structure of the...
Report of Secondary Outcomes in NSABP B-40 Indicates Improved Overall Survival With Neoadjuvant Plus Adjuvant Bevacizumab in Early Breast Cancer
The phase III NSABP B-40 (NRG Oncology) trial showed that the addition of bevacizumab (Avastin) to docetaxel-based neoadjuvant chemotherapy improved pathologic complete response rate, the primary endpoint, in patients with early HER2-negative breast cancer. In a report of secondary outcomes in The...
European Trial Indicates No Additional Benefit From Preoperative Radiotherapy Following Neoadjuvant Chemotherapy in Stage IIIA/N2 NSCLC
In a phase III trial reported in The Lancet, Pless et al in the Swiss Group for Clinical Cancer Research found that adding preoperative radiation following neoadjuvant chemotherapy did not appear to improve outcomes vs neoadjuvant chemotherapy alone in patients with stage IIIA/N2 non–small...
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
In two phase III trials reported in The Lancet Oncology, Rapoport et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...
Rolapitant Reduced Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy or Anthracycline/Cyclophosphamide
In a phase III study reported in The Lancet Oncology, Schwartzberg et al found that the addition of rolapitant to serotonin (5-HT3) receptor antagonist and dexamethasone treatment significantly improved complete response rates in prevention of chemotherapy-induced nausea and vomiting in patients...
Pembrolizumab Cutaneous Adverse Events May Predict Better Response
In a single-center retrospective review reported in JAMA Dermatology, Sanlorenzo et al found that cutaneous adverse events in patients receiving the anti–PD-1 agent pembrolizumab (Keytruda), currently approved for treatment of melanoma, may indicate better treatment response. Study Details...
Adjuvant Taxane-Based Chemotherapy Is Not Associated With Increased Risk of Lymphedema, Study Finds
In women with breast cancer, taxane-based chemotherapy—docetaxel and paclitaxel—did not appear to increase the incidence of lymphedema, according to a study by Swaroop et al in Breast Cancer Research and Treatment. However, the investigators did note that adjuvant chemotherapy with...
Persistent HPV16 DNA in Post-Treatment Oral Rinse Associated With Poor Prognosis in HPV-Related Oropharyngeal Carcinoma
In a prospective cohort study reported in JAMA Oncology, Rettig et al found that persistent human papillomavirus (HPV) type 16 DNA in post-treatment oral rinses was associated with a poorer prognosis in patients with HPV-related oropharyngeal cancer. The study included 124 patients treated with...
Similar Survival With Salvage Surgery After Definitive Chemoradiotherapy vs Neoadjuvant Chemotherapy Followed by Esophagectomy in Esophageal Cancer
In a retrospective European study reported in the Journal of Clinical Oncology, Markar et al found that salvage esophagectomy after definitive chemoradiotherapy was associated with similar survival outcomes vs neoadjuvant chemotherapy followed by planned esophagectomy in treatment of...
FDA Grants Regular Approval to Brentuximab Vedotin as Post-Transplant Consolidation Therapy for High-Risk Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris) as post–autologous hematopoietic stem cell transplantation consolidation treatment for patients with classical Hodgkin lymphoma at high risk of relapse or progression, Seattle Genetics has announced. The...
Long-Term Results of Dutch CROSS Trial Indicate Continued Survival Benefit With Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Initial results of the Dutch phase III CROSS trial showed a significant 5-year overall survival benefit with the addition of neoadjuvant chemoradiotherapy to surgery after a median 45-month follow-up in patients with squamous cell carcinoma or adenocarcinoma of the esophagus or esophagogastric...
Study Identifies Gene Mutations Associated With Aggressive Multiple Myeloma
Using whole-exome sequencing on newly diagnosed patients with multiple myeloma, British researchers identified 15 genes that were significantly mutated in a subset of patients and mapped how these mutations related to long-term survival. They found 90% of patients with very aggressive disease who...
Study Reveals Effects of Chemoradiation in Brains of Glioblastoma Patients
A study from Massachusetts General Hospital (MGH) Cancer Center researchers—the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients—revealed not only specific structural changes within patients’ brains, but also...
Adding Oxaliplatin to Preoperative Chemoradiotherapy and Postoperative Chemotherapy Improves Disease-Free Survival in Locally Advanced Rectal Cancer
Final results of the German phase III CAO/ARO/AIO-04 trial reported in The Lancet Oncology by Rödel et al showed that adding oxaliplatin to fluorouracil (5-FU)–based neoadjuvant chemoradiation and postoperative chemotherapy improved disease-free survival in patients with locally advanced ...
Combining Interleukin-2 With Imiquimod and Topical Retinoid Therapy May Be Effective Against Cutaneous Metastatic Melanoma
A novel combination therapy appears to be effective in treating patients with melanoma skin metastases, according to new research from the University of California (UC) Davis. Led by Emanual Maverakis, MD, of the UC Davis Department of Dermatology, the research found that interleukin-2...
Researchers Identify Nerve-Guiding Protein That May Be Associated With Pancreatic Cancer Metastasis
Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer and were published by Foley et...
Reduced Short-Term Effects With Hypofractionated Whole-Breast Irradiation After Breast-Conserving Surgery
In a randomized trial reported in JAMA Oncology, Shaitelman et al found that hypofractionated whole-breast irradiation resulted in reduced short-term effects compared with conventional fractionation in women with stage 0 to II breast cancer undergoing breast-conserving surgery. Study Details In...
French Phase II Trial Suggests No Benefit of Adding Bevacizumab to Paclitaxel in Advanced Angiosarcoma
In a French phase II trial reported in the Journal of Clinical Oncology, Ray-Coquard et al found no apparent benefit of paclitaxel plus bevacizumab (Avastin) compared with weekly paclitaxel in patients with inoperable locally advanced or metastatic angiosarcoma. Study Details In this...
Medullablastomas Can Be Classified Noninvasively at Diagnosis
Medulloblastoma, the most commonly occurring malignant brain tumor in children, can be classified into four subgroups, each with a different risk profile requiring subgroup-specific therapy. Currently, subgroup determination is done after surgical removal of the tumor. Investigators at...
Investigational Topical Gel Is Safe and Effective in Patients With Cutaneous T-Cell Lymphoma, Phase I Trial Shows
Results of a phase I trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early-stage cutaneous T-cell lymphoma. Currently, there is no cure for...
Key Genetic Factor in Cell Proliferation in Moles Identified
Scientists have known for years that a mutation in the BRAF gene makes moles start to grow but until now have not understood why they sometimes do not become cancerous. Researchers from the Perelman School of Medicine at the University of Pennsylvania have identified a major genetic factor that...
Addition of Docetaxel to Androgen-Deprivation Therapy Improves Survival in Metastatic Prostate Cancer
In the phase III E3805 trial reported in The New England Journal of Medicine, Sweeney et al found that chemohormonal therapy with docetaxel plus androgen-deprivation therapy produced a significant 13.6-month increase in median overall survival vs androgen-deprivation therapy alone in men with...
ASCO Statement: Improving the Evidence Base for Treating Older Adults With Cancer
Older persons are the fastest growing segment of the U.S. population and account for the majority of cancer diagnoses and deaths and the majority of cancer survivors. However, since this population is underrepresented in clinical trials, the evidence base for treating older patients is poor. As...
17-Year Follow-up Indicates Early but Not Overall Reduction in Breast Cancer Mortality With Annual Mammography Screening at Age 40-49 Years
The 17-year follow-up in the UK Age trial, reported in The Lancet Oncology by Moss et al, indicated a reduction in breast cancer mortality during the first 10 years after diagnosis but not thereafter among women invited for annual mammography screening from age 40 to 49 years compared with...
Proteins Found in Urine May Serve as Biomarker for Early-Stage Pancreatic Cancer
A team of researchers at Barts Cancer Institute–Queen Mary University of London has discovered a combination of three proteins found at high levels in urine that can accurately detect early-stage pancreatic cancer. The discovery could lead to a noninvasive, inexpensive test to...
Biomarker Signature May Predict Aggressive Disease in African American Men With Prostate Cancer
In a study reported in Journal of Clinical Oncology, Yamoah et al identified a biomarker signature that may predict aggressive disease in African American men with prostate cancer. Study Details In the study, distribution of mRNA expression levels of 20 biomarkers associated with prostate cancer...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Van Poznak et al, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer. The statement is based on an ASCO expert panel assessment of systematic reviews, ...
No Difference in Overall Survival With Addition of Quinolone Derivative Vosaroxin to Cytarabine in Relapsed or Refractory AML
In a phase III VALOR trial reported in The Lancet Oncology, Ravandi et al found that the addition of the quinolone derivative vosaroxin to cytarabine did not significantly improve overall survival in patients with relapsed or refractory acute myeloid leukemia (AML). However, differences favoring...
